Skip to content

Celecoxib effects on COVID-19 patients

Evaluation of short-term effects of Celecoxib on clinical improvement of COVID-19 patients: A randomized clinical trial study

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200907048644N1
Enrollment
60
Registered
2020-10-04
Start date
2020-09-22
Completion date
Unknown
Last updated
2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19

Interventions

Intervention 1: Intervention group: 40 patients receiving routine + celecoxib treatments. This group is divided into two subgroups (20 people in each group):A dose received 200mg / day (in divided dos

Sponsors

Zahedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Subjects with COVID-19 in the second phase of the disease Shortness of breath, chest pain with or without fever equal to or greater than 38 'C Blood oxygen saturation (SpO2) between 90-93% Adult patients with COVID-19 with moderate pulmonary involvement and hospitalized in the general ward who have been diagnosed and confirmed with coronavirus by conventional diagnostic methods such as sequencing or qRT-PCR and CT (within 48 hours of admission) Age range of patients between 18-65 years Existence of pneumonia in lung CT scan with involvement of maximum 3 or 4 lung lobes or less than one third of the volume of each lobe or infection of one or two lobes with larger area Patients informed consent

Exclusion criteria

Exclusion criteria: Patients under 18 or over 65 years old Patients with severe and advanced disease are admitted to the intensive care unit Participate in another clinical trial Shock and critical illness (requires ventilator and organ failure) Patients with organ dysfunction such as renal failure and liver damage, patients with asthma Taking certain medications such as furosemide or Lasex, lithium, ACE2 inhibitors Pregnancy People with medical history such as high blood pressure, autoimmune diseases and ..

Design outcomes

Primary

MeasureTime frame
Lung function (Pulmonary infiltration, GGO, Edema). Timepoint: Every week. Method of measurement: CT Scan.;Respiratory Rate, SpO2, PaO2/FiO2. Timepoint: Every day. Method of measurement: Physical examination.;Body Temperature. Timepoint: Every day. Method of measurement: Thermometer.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRoghayh Sheervalilou

Zahedan University of Medical Sciences

sheervalilour@tbzmed.ac.ir+98 54 3329 5817

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026